Siberian Ginseng Total Flavonoids Extract Wins Award from Heilongjiang Province Pharmaceutical Industry Association
HARBIN, China, Dec. 2, 2010 /PRNewswire-Asia-FirstCall/ — China Botanic Pharmaceutical Inc. (NYSE Amex: CBP) (“China Botanic” or the “Company”), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines (“TCM”), today announced that the Company’s Siberian Ginseng (Acanthopanax) Total Flavonoids Extract (“Siberian Ginseng Flavonoids Extract”) was awarded the third prize by the recently held Heilongjiang Province Science and Technological Progress assessment. China Botanic’s Siberian Ginseng Flavonoids Extract was nominated by the Heilongjiang Province Pharmaceutical Industry Association and judged by the pharmaceutical industry expert review group.
Siberian Ginseng Flavonoids Extract has been shown to be particularly beneficial in treating nervous system maladies and relieving depression. It has been independently researched and developed by the Company, utilizing its innovative technology to obtain uniquely effective plant extracts. The process utilized in deriving the flavonoid compounds from Siberian Ginseng is exclusive to the Company, and a national patent application has been submitted to protect China Botanic’s intellectual property. During the process, unusually pure flavonoid extracts are obtained with very few of the impurities introduced by other techniques. The results can be sold either as plant extracts or they can be further processed into such Total Flavonoids products as freeze-dried powder injection or soft capsule.
“We are pleased that our Siberian Ginseng Flavonoids extract has been honored by the Provincial Scientific and Technological Progress jury,” said Mr. Shaoming Li, the Chairman and CEO of China Botanic Pharmaceutical Inc. “It is great to see recognition of our significant investment in R&D projects, which are led by a team of experts in botanical medicine. The result has been our unique line of pure and effective plant-based remedies. China Botanic will continue to innovate as we stride toward our goal of becoming the world’s leading producer of all-natural treatments for depression.”
ABOUT CHINA BOTANIC PHARMACEUTICAL INC.
China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines (“TCM”), in the People’s Republic of China. All of the Company’s products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China.
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management’s beliefs, assumptions and expectations of the Company’s future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company’s ability to achieve its financial guidance, ability to manage expansion of its operations effectively, competition in the marketing and sales of its products, and other factors detailed in the Company’s annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
Company Contact: CCG Investor Relations: China Botanic Pharmaceutical Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: firstname.lastname@example.org Email: email@example.com Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: firstname.lastname@example.org
SOURCE China Botanic Pharmaceutical Inc.